Parameters | All patients (N = 56) | Controlled HT (N = 25) | Uncontrolled HT (N = 31) | P value |
---|---|---|---|---|
At diagnosis | ||||
Age, y (mean ± SD) | 12.2 ± 3.67 | 13.09 ± 3.22 | 11.48 ± 3.9 | 0.11 |
Male, N (%) | 40 (71.4) | 19 (76) | 21 (67.7) | 0.56 |
Diagnosis BMI z-score, median (IQR) | 2.5 (1.45, 2.86) | 2.51 (1.43, 2.78) | 2.5 (1.35, 3.18) | 0.79 |
Office SBP index, median (IQR) | 1.04 (1, 1.08) | 1.04 (1, 1.09) | 1.03 (1, 1.08) | 0.66 |
Office DBP index, median (IQR) | 0.96 (0.91, 1.04) | 0.97 (0.9, 1.05) | 0.96 (0.91, 1.04) | 0.81 |
eGFR (ml/min/1.73m2), mean ± SD | N = 52 108.89 ± 27.05 | N = 24 103.3 ± 30.12 | N = 28 113.68 ± 23.62 | 0.17 |
At Follow-up | ||||
Age, y (mean ± SD) | 13.91 ± 3.86 | 14.72 ± 3.34 | 13.25 ± 4.17 | 0.16 |
The 1st ABPM after treating HT (y), median (IQR) | 1 (0.5, 2.18) | 1.11 (0.5, 2.5) | 0.9 (0.4, 2) | 0.62 |
BMI z score, mean ± SD | 2.13 ± 1.56 | 1.96 ± 1.06 | 2.26 ± 1.87 | 0.49 |
BMI z score change, median (IQR) | -0.14 (-0.51, 0.14) | -0.39 (-0.57, 0.12) | 0.01 (-0.39, 0.22) | 0.032* |
24-hr ABPM SBP index, mean ± SD | 0.98 ± 0.08 | 0.92 ± 0.05 | 1.04 ± 0.06 | < 0.001 |
24-hr ABPM DBP index, mean ± SD | 0.89 ± 0.08 | 0.85 ± 0.05 | 0.93 ± 0.07 | < 0.001 |
eGFR (ml/min/1.73m2), median (IQR) | N = 49 106.49 (90.94,120.32) | N = 19 105.94 (84.37, 119.69) | N = 30 108.06 (91.57, 122.81) | 0.4 |
eGFR change (ml/min/1.73m2), median (IQR) | N = 45 0.36 (-17.46, 9.52) | N = 19 -5.18 (-22.01, 11.76) | N = 26 1.23 (-15.62, 9.05) | 0.37 |
Number of anti-HT drugs per patient, mean ± SD | N = 41 1.34 ± 0.53 | N = 17 1.35 ± 0.49 | N = 24 1.33 ± 0.57 | 0.91 |
Proteinuria, N (%) | N = 7 1 (14.29) | N = 3 0 (0) | N = 4 1 (25) | 0.35 |
ACEI monotherapy, N | 7 | 4 | 3 | 0.26 |
ARB monotherapy, N | 2 | 2 | 0 | 0.07 |
CCB monotherapy, N | 15 | 5 | 10 | 0.49 |